Małgorzata Nowicka
Roche (Switzerland) · 151 works · 3,553 citations · h-index 21
Top works
- Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets
- CyTOF workflow: Differential discovery in high-throughput high-dimensional cytometry datasets
- diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering
- Isoform prefiltering improves performance of count-based methods for analysis of differential transcript usage
- DRIMSeq: a Dirichlet-multinomial framework for multivariate count outcomes in genomics
- T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments
- DRIMSeq: a Dirichlet-multinomial framework for multivariate count outcomes in genomics
- ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
- Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
- Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
- Prevalence of estrogen receptor alpha PvuII and XbaI polymorphism in population of Polish postmenopausal women.
- Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial
- CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets
- CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets
- Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).
- PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.